Triethylenetetramine dihydrochloride - CAS 38260-01-4
Catalog: |
BB023600 |
Product Name: |
Triethylenetetramine dihydrochloride |
CAS: |
38260-01-4 |
Synonyms: |
N'-[2-(2-aminoethylamino)ethyl]ethane-1,2-diamine;dihydrochloride |
Application: |
A selective CuII-chelator |
IUPAC Name: | N'-[2-(2-aminoethylamino)ethyl]ethane-1,2-diamine;dihydrochloride |
Description: | Triethylenetetramine Hydrochloride is a selective CuII-chelator, undergoing trials for the treatment of heart failure in patients with diabetes. |
Molecular Weight: | 219.16 |
Molecular Formula: | C6H20Cl2N4 |
Canonical SMILES: | C(CNCCNCCN)N.Cl.Cl |
InChI: | InChI=1S/C6H18N4.2ClH/c7-1-3-9-5-6-10-4-2-8;;/h9-10H,1-8H2;2*1H |
InChI Key: | WYHIICXRPHEJKI-UHFFFAOYSA-N |
Boiling Point: | 266.5 ℃ at 760 mmHg |
Melting Point: | >161 ℃ (subl.) |
Purity: | ≥ 95 % |
Density: | 0.958 g/cm3 |
Solubility: | Soluble in DMSO |
Appearance: | White to off-white solid |
Storage: | Store at -20 ℃ |
MDL: | MFCD00012889 |
LogP: | 1.86940 |
Quality Standard: | Enterprise standard |
GHS Hazard Statement: | H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation] |
Precautionary Statement: | P261, P264, P271, P280, P302+P352, P304+P340, P305+P351+P338, P312, P321, P332+P313, P337+P313, P362, P403+P233, P405, and P501 |
Signal Word: | Warning |
Publication Number | Title | Priority Date |
WO-2021195671-A1 | Process for preparing trientine dihydrochloride | 20200327 |
KR-102121755-B1 | An electroless nickel plating solution easy to convert use | 20200220 |
US-11000540-B1 | Treatment for reducing adverse events including chemotherapy discomfort and other conditions | 20191122 |
US-2021154225-A1 | Treatment for reducing adverse events including chemotherapy discomfort and other conditions | 20191122 |
US-2021213131-A1 | Treatment for reducing adverse events including chemotherapy discomfort and other conditions | 20191122 |
PMID | Publication Date | Title | Journal |
24306314 | 20140601 | Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies | Investigational new drugs |
23541064 | 20131210 | Trientine reduces BACE1 activity and mitigates amyloidosis via the AGE/RAGE/NF-κB pathway in a transgenic mouse model of Alzheimer's disease | Antioxidants & redox signaling |
23403016 | 20130801 | Triethylenetetramine prevents insulin aggregation and fragmentation during copper catalyzed oxidation | European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V |
23202417 | 20130507 | Complex formation equilibria of Cu(II) and Zn(II) with triethylenetetramine and its mono- and di-acetyl metabolites | Dalton transactions (Cambridge, England : 2003) |
23010628 | 20121201 | Synthesis, spectroscopic characterization and crystal structure of novel NNNN-donor μ-bis(bidentate) tetraaza acyclic Schiff base ligands | Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy |
Complexity: | 49.7 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 3 |
Defined Atom Stereocenter Count: | 0 |
Defined Bond Stereocenter Count: | 0 |
Exact Mass: | 218.1065020 |
Formal Charge: | 0 |
Heavy Atom Count: | 12 |
Hydrogen Bond Acceptor Count: | 4 |
Hydrogen Bond Donor Count: | 6 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 218.1065020 |
Rotatable Bond Count: | 7 |
Topological Polar Surface Area: | 76.1 Å2 |
Undefined Atom Stereocenter Count: | 0 |
Undefined Bond Stereocenter Count: | 0 |
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Nitrogen Compounds
Customers Also Viewed
INDUSTRY LEADERS TRUST OUR PRODUCTS